La chaîne d'options affiche les données clés des options sur actions de UiPath à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour UiPath..

UiPath (NYSE:PATH) Stock, Chaîne d'Options

UIPATH INC - CLASS A

UiPath

UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.

UiPath Inc

Pathfinder Bancorp Inc

PATHFINDER CELL THERAPY by Pathfinder Cell Therapy, Inc.

Pathfinder Cell Therapy Inc

Pathfinder Ventures Inc

PATHFINDER VENTURES INC by PATHFINDER VENTURES INC.

Pathward Financial Inc

Morgan Stanley analyst Sanjit Singh maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $12 to $15.

News

Price Target

Analyst Ratings

PATH

Morgan Stanley Maintains Equal-Weight on UiPath, Raises Price Target to $15

General

HCLTech and UiPath Announce Strategic Partnership To Drive Large-Scale Transformation For Enterprises Across Industries

Canaccord Genuity analyst Kingsley Crane maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Buy and raises the price target from $14 to $16.

Canaccord Genuity Maintains Buy on UiPath, Raises Price Target to $16

Benzinga examined the prospects for <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noreferrer noopener">many investors' favorite stocks</a> over the last week — here's a look at some of our top stories.
In May, U.S. stocks recorded their strongest monthly rally since November 2023, driven by easing trade tensions and robust tech earnings. The S&amp;P 500 rose 6.2%, and the Nasdaq Composite surged 9.6%, returning both indices to positive territory for the year. The "Magnificent Seven" tech giants led the charge, with Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) stock climbing 24% after reporting a 70% year-over-year revenue increase.
Despite the tech sector's dominance, investors anticipate a broader market rally, citing improving earnings in sectors like industrials, consumer staples, and financials. Analysts expect the earnings growth gap between the Magnificent Seven and the rest of the S&amp;P 500 to narrow in 2025.
However, uncertainties remain. A U.S. court ruling declared President Donald Trump's recent tariffs illegal, though the decision was promptly appealed. Analysts warn that renewed tariffs, particularly on chips and pharmaceuticals, could threaten the sustainability of recent market gains.
Benzinga provides daily reports on the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look.

The Bulls
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655507/tech-analyst-expects-palantir-stock-to-rise-above-400-as-ai-revolution-kicks-into-gear">"Tech analyst expects Palantir stock to rise above $400 as AI revolution kicks into gear"</a>, by Adam Eckert, reports that Wedbush analyst Dan Ives predicts Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) will surpass $400 per share and reach a $1 trillion market cap within a few years, citing its leadership in AI and calling it the "Messi of AI."
<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45675006/nvidia-stock-has-significant-upside-as-ai-godfather-jensen-huang-delivers-another-robust-quarter">"Nvidia stock has ‘significant upside' as AI ‘godfather' Jensen Huang delivers another ‘robust quarter'"</a>, by Chris Katje, reports that Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares rose after the company beat Q1 estimates and analysts projected a market cap of up to $5 trillion, citing surging demand for its Blackwell AI chips and growth in AI infrastructure despite China export restrictions.
<a href="https://www.benzinga.com/news/earnings/25/05/45682895/ulta-beauty-stock-climbs-after-better-than-expected-q1-report-raised-fiscal-2025-outlook">"Ulta Beauty stock climbs after better-than-expected Q1 report, raised fiscal 2025 outlook"</a>, by Erica Kollmann, reports that Ulta Beauty Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) shares surged over 11% after the company exceeded Q1 earnings and revenue expectations, posting $6.70 EPS and $2.85 billion in sales, and raised its fiscal 2025 guidance amid strong demand for skincare and fragrance products.
For additional bullish calls of the past week, check out the following:
<a href="https://www.benzinga.com/news/earnings/25/05/45683235/uipath-stock-surges-on-q1-earnings-beat-raised-guidance-this-was-a-milestone-quarter">UiPath Stock Surges On Q1 Earnings Beat, Raised Guidance: ‘This Was A Milestone Quarter'</a>
<a href="https://www.benzinga.com/government/regulations/25/05/45650179/uranium-stocks-hit-17-year-highs-as-mays-rally-marks-best-month-on-record">Uranium Stocks Hit 17-Year Highs As May's Rally Marks Best Month On Record</a>
<a href="https://www.benzinga.com/general/biotech/25/05/45648350/why-is-gsk-partner-spero-therapeutics-stock-skyrocketing-on-wednesday">Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?</a>

The Bears
<a href="https://www.benzinga.com/news/earnings/25/05/45681892/marvell-technology-stock-slips-after-q1-results-details">"Marvell Technology stock slips after Q1 results: Details"</a>, by Erica Kollmann, reports that Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) shares fell over 3% after the company posted Q1 adjusted earnings of 62 cents per share on $1.9 billion in revenue—both slightly above analyst estimates—but investors showed muted enthusiasm despite strong AI-driven data center demand and a raised Q2 revenue forecast of $2 billion.
<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45692578/regeneron-sanofi-stock-falls-after-uneven-smokers-lung-drug-data">"Regeneron, Sanofi stock falls after uneven smoker's lung drug data"</a>, by Vandana Singh, reports that Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) and Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) shares declined after their experimental COPD drug, itepekimab, showed a 27% reduction in exacerbations in one Phase 3 trial but failed to meet the primary endpoint in a second trial, raising concerns about its efficacy.
<a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45645056/gold-etf-bleeds-money-at-fastest-pace-in-3-years-is-the-safe-haven-trade-over">"Gold ETF bleeds money at fastest pace in 3 years — is the safe-haven trade over?"</a>, by Piero Cingari, reports that the SPDR Gold Shares ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) experienced $2.1 billion in outflows in May — its worst since July 2022 — as easing U.S.-China tensions and a surging S&amp;P 500 shifted investor appetite toward riskier assets, though Goldman Sachs still forecasts gold reaching $3,700 per ounce by year-end, driven by central bank demand and long-term macro risks.
For more bearish takes, be sure to see these posts:
<a href="https://www.benzinga.com/news/stock-split/25/05/45679654/mullen-automotive-stock-is-tumbling-thursday-whats-driving-the-action">Mullen Automotive Stock Is Tumbling Thursday: What's Driving The Action?</a>
<a href="https://www.benzinga.com/general/biotech/25/05/45655674/rocket-pharmas-gene-therapy-future-clouded-by-regulatory-uncertainty">Rocket Pharma's Gene Therapy Future Clouded By Regulatory Uncertainty</a>
<a href="https://www.benzinga.com/general/biotech/25/05/45624650/why-is-neuropace-stock-falling-after-epilepsy-treatment-study-data">Why Is NeuroPace Stock Falling After Epilepsy Treatment Study Data?</a>
Keep up with all the latest breaking news and trading ideas by following <a href="https://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener">Benzinga</a><a href="http://twitter.com/Benzinga" target="_blank" rel="noreferrer noopener"> on X</a>.
Image created using artificial intelligence via Midjourney.

Markets

MRVL

MULN

NPCE

NVDA

PLTR

RCKT

REGN

SPRO

ULTA

Benzinga Bulls And Bears: Nvidia, Palantir, Marvell Technology — And Markets Rallied In May

UiPath, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) &nbsp;shares are trading higher after the company reported better-than-expected first-quarter results, issued second-quarter sales guidance above estimates, <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">and raised its FY26 guidance</a>.
On Thursday, the company reported revenue of&nbsp;$356.62 million, versus&nbsp;estimates&nbsp;of $332.87 million, and adjusted EPS of&nbsp;11 cents, <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45683235/uipath-stock-surges-on-q1-earnings-beat-raised-guidance-this-was-a-milestone-quarter" rel="noreferrer noopener">exceeding the estimates of 10 cents</a>.
The company raised its fiscal 2026 forecast from a range of $1.52 billion to $1.53 billion to a new range of $1.549 billion to $1.554 billion versus <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">estimates of $1.53 billion</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/25/05/45687166/apple-may-see-fewer-searches-in-safari-but-google-ceo-sundar-pichai-insists-ai-is-fueling-overall-query-growth-far-from-a-zero-sum-game" rel="noreferrer noopener">Apple May See Fewer Searches In Safari, But Google CEO Sundar Pichai Insists AI Is Fueling Overall Query Growth: &#8216;Far From A Zero-Sum Game&#8217;</a>
Many analysts raised the price forecast on the <a target="_blank" href="https://www.benzinga.com/quote/PATH/analyst-ratings" rel="noreferrer noopener">stock following the results</a>.
RBC Capital analyst Matthew Hedberg maintained a Sector Perform rating and raised the price target from&nbsp;$13&nbsp;to&nbsp;$15.
After a challenging initial FY26 guide and miss to end last year due to public sector issues, UiPath showed encouraging progress in that vertical through proactive engagement, said the analyst.
According to the analyst, the Federal renewals met expectations, with some agencies even outperforming, though budget finalizations still present some pressure.
UiPath is seeing early success with agentic initiatives, including over 250,000 agent runs on Agent Builder and 11,000 process instances powered by Maestro since their preview releases, Hedberg remarked in an analyst note.
The analyst said that despite ongoing macroeconomic variability, management expressed continued prudence in their FY26 guidance, which was nonetheless raised across the board.
Hedberg highlighted the company&#8217;s optimism about its agentic AI opportunities and early customer interest, though significant revenue contributions from this area are not anticipated until FY27.
Needham analyst Scott Berg reiterated a Hold rating.
In an analyst note, Berg observed that UiPath posted a solid upside in revenue and operating income versus low Street expectations, primarily driven by strong license revenue that exceeded their estimate by 24%.
However, net new ARR came in at $27 million, a 39% year-over-year decrease (compared to a consensus of +$22.6 million), which the analyst attributes to lingering impacts from go-to-market (GTM) changes and execution improvements from FY25.
Berg pointed out that the current guidance indicates an increasingly second-half weighted performance, with 76% of net new ARR expected in the second half versus 57% in FY25, suggesting a moderately more challenging ramp-up.
The guidance comes despite continued declines in key metrics, including Net Revenue Retention (NRR), which dropped to 108% in the quarter, Berg added.
KeyBanc analyst Jason Celino retained a Sector Weight rating on the stock.
The analyst revised the FY26 estimates to account for the first quarter results and updated the outlook, expecting revenue of $1.552 billion (vs. $1.528 billion prior &amp; consensus of $1.522 billion) for FY26.
While the analyst finds the improved results and advancements within the public sector encouraging, he maintained the rating due to the early stage of the agentic AI opportunity and ongoing macroeconomic uncertainty.
Truist analyst Terry Tillman raised the price forecast from $12 to $13 while maintaining a Hold rating.
In an analyst note, Tillman underscored that the company surpassed their estimates, with particularly strong beats in total revenue and non-GAAP operating income.
Positive traction appears to be building from agentic solutions, the new partner program, and the recently acquired Peak, among other initiatives, which led the analyst to raise the estimates based on the improved outlook.
In particular, Tillman now sees revenue of $1.547 billion (vs. $1.527 billion earlier) compared to a consensus of $1.522 billion for FY26.
The analyst emphasized the company&#8217;s narrative is still a work in progress concerning the improvement of its annualized renewal run rate (ARR) and the return of net new ARR to a trajectory of robust growth.
Price Action: PATH shares are trading higher by 1.20% to $13.10 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45686378/openai-fights-to-keep-countersuit-alive-against-elon-musk-over-profit-shift-calls-his-974-billion-bid-a-media-stunt" target="_blank" rel="noreferrer noopener">OpenAI Wants Its Fraud And Media Manipulation Countersuit Against Elon Musk Kept Alive, Labels His $97.4 Billion Bid A Stunt</a></li>
</ul>
Photo by Ian Dewar Photography via Shutterstock

Analysts Applaud UiPath's AI Traction, But Net New ARR Slide Sparks Caution

BMO Capital analyst Keith Bachman maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Market Perform and raises the price target from $11.5 to $15.5.

BMO Capital Maintains Market Perform on UiPath, Raises Price Target to $15.5

Evercore ISI Group analyst Kirk Materne maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a In-Line and raises the price target from $11 to $15.

Evercore ISI Group Maintains In-Line on UiPath, Raises Price Target to $15

UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) reported better-than-expected first-quarter financial results and raised its FY26 guidance on Thursday.
UiPath reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of 10 cents per share. The company reported quarterly sales of $356.62 million which beat the analyst consensus estimate of $332.87 million.
"This was a milestone quarter for UiPath, marked by the launch of our agentic automation platform, a meaningful step forward in our product evolution. We're encouraged by the early response from customers, partners, and the broader ecosystem, which underscores the growing interest in agentic automation as a key part of the enterprise automation journey," said Daniel Dines, founder and CEO of UiPath.
UiPath expects second-quarter revenue to be between $345 million and $350 million versus estimates of $333.12 million, according to Benzinga Pro. The company also raised its fiscal 2026 forecast from a range of $1.52 billion to $1.53 billion to a new range of $1.549 billion to $1.554 billion versus estimates of $1.53 billion.
UiPath shares gained 0.3% to trade at $12.98 on Friday.
These analysts made changes to their price targets on UiPath following earnings announcement.
<ul class="wp-block-list">
<li>Wells Fargo analyst Michael Turrin maintained UiPath with an Equal-Weight rating and raised the price target from $11 to $12.</li>
<li>RBC Capital analyst Matthew Hedberg maintained the stock with a Sector Perform and raised the price target from $13 to $15.</li>
<li>Scotiabank analyst Nick Altmann maintained UiPath with a Sector Perform and raised the price target from $12 to $13.</li>
<li>DA Davidson analyst Gil Luria maintained the stock with a Neutral and raised the price target from $11 to $14.</li>
<li>Barclays analyst Raimo Lenschow maintained UiPath with an Equal-Weight rating and raised the price target from $12 to $14.</li>
<li>Truist Securities analyst Terry Tillman maintained the stock with a Hold and raised the price target from $12 to $13.</li>
</ul>
Considering buying PATH stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/PATH/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30125516/image-418-1024x573.png" alt="" class="wp-image-933540" style="width:647px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30125516/image-418-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30125516/image-418-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30125516/image-418-768x429.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/30125516/image-418.png 1132w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

Earnings

Trading Ideas

These Analysts Boost Their Forecasts On UiPath After Upbeat Q1 Results

Truist Securities analyst Terry Tillman maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Hold and raises the price target from $12 to $13.

Truist Securities Maintains Hold on UiPath, Raises Price Target to $13

Barclays analyst Raimo Lenschow maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $12 to $14.

Barclays Maintains Equal-Weight on UiPath, Raises Price Target to $14

DA Davidson analyst Gil Luria maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Neutral and raises the price target from $11 to $14.

DA Davidson Maintains Neutral on UiPath, Raises Price Target to $14

Scotiabank analyst Nick Altmann maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and raises the price target from $12 to $13.

Scotiabank Maintains Sector Perform on UiPath, Raises Price Target to $13

RBC Capital analyst Matthew Hedberg maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Sector Perform and raises the price target from $13 to $15.

RBC Capital Maintains Sector Perform on UiPath, Raises Price Target to $15

Wells Fargo analyst Michael Turrin maintains UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) with a Equal-Weight and raises the price target from $11 to $12.

Wells Fargo Maintains Equal-Weight on UiPath, Raises Price Target to $12

Across the recent three months, 13 analysts have shared their insights on UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">9</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated UiPath and provided 12-month price targets. The average target is $11.81, accompanied by a high estimate of $14.00 and a low estimate of $10.00. This current average represents a 22.05% decrease from the previous average price target of $15.15. 
<img src="https://www.benzinga.com/files/images/story/2025/1748610015_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of UiPath by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$13.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$11.50</td>
<td>$16.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$13.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Kingsley Crane</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$14.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Kirk Materne</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Nick Altmann</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jeff Hickey</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Michael Turrin</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$11.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Siti Panigrahi</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brad Sills</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$10.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UiPath. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of UiPath compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for UiPath's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of UiPath's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/PATH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on UiPath analyst ratings.</a>
<h2>Delving into UiPath's Background</h2>
UiPath Inc offers an end-to-end cross-application enterprise automation platform principally with computer vision technology and user interface automations in its initial RPA offering, which remains the foundation of the platform. The platform leverages a range of automation technologies including robotic process automation, application programming interface, and artificial intelligence. UiPath's solution can automate a broad range of repetitive tasks across industries including claims processing, employee onboarding, invoice to cash, loan applications, and customer service.
<h3>Understanding the Numbers: UiPath's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Over the 3M period, UiPath showcased positive performance, achieving a revenue growth rate of 4.54% as of 31 January, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: UiPath's net margin excels beyond industry benchmarks, reaching 12.23%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): UiPath's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.9%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): UiPath's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.87%, the company showcases efficient use of assets and strong financial health.
Debt Management: UiPath's debt-to-equity ratio is below the industry average at 0.04, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UiPath Stock: A Deep Dive Into Analyst Perspectives (13 Ratings)

WIIM

UiPath shares are trading higher after the company reported better-than-expected Q1 financial results, issued Q2 sales guidance above estimates, and raised its FY26 guidance.

Needham analyst Scott Berg reiterates UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from Hold to Hold.

Reiteration

Needham Reiterates Hold on UiPathto Hold

<h3>Gainers</h3>
<ul>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) stock increased by 14.5% to $2.52 during Friday's pre-market session. The market value of their outstanding shares is at $152.1 million. </li>
<li>UiPath (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares moved upwards by 11.97% to $14.49. The market value of their outstanding shares is at $7.9 billion. As per the press release, Q1 earnings came out yesterday. </li>
<li>MicroCloud Hologram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) stock rose 10.56% to $7.43. The company's market cap stands at $38.0 million. </li>
<li>LightPath Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPTH#NASDAQ">LPTH</a>) shares moved upwards by 10.16% to $3.25. The company's market cap stands at $139.4 million. </li>
<li>Ascent Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) shares increased by 7.47% to $1.7. The company's market cap stands at $3.0 million. </li>
<li>Diginex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DGNX#NASDAQ">DGNX</a>) shares increased by 7.33% to $62.48. The market value of their outstanding shares is at $1.4 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Signing Day Sports (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SGN#AMEX">SGN</a>) stock decreased by 9.4% to $2.3 during Friday's pre-market session. The market value of their outstanding shares is at $8.3 million. </li>
<li>HeartCore Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTCR#NASDAQ">HTCR</a>) stock decreased by 8.95% to $0.67. The market value of their outstanding shares is at $14.8 million. </li>
<li>PicoCELA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCLA#NASDAQ">PCLA</a>) shares declined by 8.85% to $0.64. The market value of their outstanding shares is at $17.4 million. </li>
<li>Sobr Safe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOBR#NASDAQ">SOBR</a>) stock fell 8.31% to $2.98. The market value of their outstanding shares is at $4.5 million. </li>
<li>AMTD Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares fell 7.97% to $2.42. The company's market cap stands at $760.6 million. </li>
<li>Actelis Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) shares fell 7.62% to $0.64. The market value of their outstanding shares is at $5.7 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ASNS

ASTI

DGNX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HTCR

LPTH

PCLA

SOBR

12 Information Technology Stocks Moving In Friday's Pre-Market Session

Shares of UiPath Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/news/earnings/25/05/45683235/uipath-stock-surges-on-q1-earnings-beat-raised-guidance-this-was-a-milestone-quarter">raised its FY26 guidance</a>.
UiPath reported quarterly earnings of 11 cents per share which beat the analyst consensus estimate of 10 cents per share. The company reported quarterly sales of $356.62 million which beat the analyst consensus estimate of $332.87 million.
UiPath shares jumped 13.2% to $14.65 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul class="wp-block-list">
<li>Bolt Projects Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSLK#NASDAQ">BSLK</a>) rose 93.4% to $3.50 in pre-market trading after dipping 20% on Thursday.</li>
<li>Nuburu, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BURU#NASDAQ">BURU</a>) surged 73.9% to $0.3513 in pre-market trading after jumping 34% on Thursday.</li>
<li>BioLineRx Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) jumped 64.7% to $6.39 in pre-market trading after the company said updated results from the pilot phase of its CheMo4METPANC Phase 2 combination trial in pancreatic cancer indicated four of eleven patients remained progression free after more than one year.</li>
<li>ECD Automotive Design, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) shares jumped 54.4% to $0.4089 in pre-market trading.</li>
<li>Red Robin Gourmet Burgers, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RRGB#NASDAQ">RRGB</a>) surged 29.4% to $4.05 in pre-market trading after the company reported better-than-expected first-quarter financial results.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) climbed 28.1% to $2.37 in pre-market trading after the company announced plans to acquire Ucare Inc. in a $150 million all-stock deal.</li>
<li>Basel Medical Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) gained 17.3% to $1.22 in pre-market trading.</li>
<li>SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) rose 16.7% to $92.45 in pre-market trading after jumping 172% on Thursday.</li>
<li>Euroholdings Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EHLD#NASDAQ">EHLD</a>) gained 11.9% to $6.85 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul class="wp-block-list">
<li>Shineco, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SISI#NASDAQ">SISI</a>) shares fell 49.9% to $0.3511 in pre-market trading after dipping 5% on Thursday.</li>
<li>CollPlant Biotechnologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLGN#NASDAQ">CLGN</a>) fell 21.8% to $3.55 in pre-market trading. CollPlant Biotechnologies announced a $3.6 million registered direct offering priced at-the-market under Nasdaq rules.</li>
<li>Medicus Pharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDCX#NASDAQ">MDCX</a>) fell 21.6% to $2.85 in pre-market trading after dipping 12% on Thursday.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) shares dipped 18.6% to $0.42 in pre-market trading after gaining 7% on Thursday.</li>
<li>Zeo Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) shares tumbled 18.1% to $2.81 in pre-market trading after the company announced it received a Nasdaq late filing notice.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) declined 16% to $0.3461 in pre-market trading after gaining 5% on Thursday.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) dipped 13.7% to $24.10 in pre-market trading after the company reported first-quarter financial results and warned tariffs could result in a gross estimated incremental cost of approximately $250 million to $300 million.</li>
<li>Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) fell 9.7% to $83.23 in today's pre-market trading after the company reported fourth-quarter results.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 8.8% to $552.00 in pre-market trading after the company and Sanofi said the AERIFY-1 study met its primary endpoint but the AERIFY-2 study didd not.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) fell 8.2% to $20.49 in pre-market trading. Newsmax filed for resale of up to 121 million shares of Class B common stock by selling stockholder.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45691209/top-3-materials-stocks-that-could-blast-off-this-month-2">Top 3 Materials Stocks That Could Blast Off This Month</a> </li>
</ul>
Photo via Shutterstock

BLRX

BMGL

BSLK

BURU

CERO

CLGN

ECDA

EHLD

ENTO

ESTC

MDCX

NMAX

RRGB

SBET

SISI

TIRX

Why UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket

UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) shares are trading higher in Thursday&#8217;s after-hours session after the company reported better-than-expected results for the first quarter and raised its <a href="https://www.benzinga.com/pressreleases/25/05/b45681131/uipath-reports-first-quarter-fiscal-2026-financial-results">full-year outlook</a>.
<ul class="wp-block-list">
<li>Q1 Revenue: $356.62 million, versus <a href="http://benzinga.com/quote/PATH/earnings">estimates</a> of $332.87 million</li>
</ul>
<ul class="wp-block-list">
<li>Q1 Adjusted EPS: 11 cents, versus estimates of 10 cents</li>
</ul>
Total revenue increased 6% compared to the prior year&#8217;s quarter. Annual recurring revenue totaled $1.69 billion as of April 30, up 12% year-over-year. The agentic automation company reported cash flow from operations of $119 million and adjusted free cash flow of $117 million. 
UiPath ended the period with $1.59 billion in cash, cash equivalents and marketable securities. 
&#8220;This was a milestone quarter for UiPath, marked by the launch of our agentic automation platform, a meaningful step forward in our product evolution. We&#8217;re encouraged by the early response from customers, partners, and the broader ecosystem, which underscores the growing interest in agentic automation as a key part of the enterprise automation journey,&#8221; said Daniel Dines, founder and CEO of UiPath.
Outlook: UiPath expects second-quarter revenue to be between $345 million and $350 million versus estimates of $333.12 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The company also raised its fiscal 2026 forecast from a range of $1.52 billion to $1.53 billion to a new range of $1.549 billion to $1.554 billion versus estimates of $1.53 billion.
&#8220;As we look to the remainder of the year, we remain focused on executing our strategy, investing in innovation and maintaining operational discipline to drive sustainable growth and profitability,&#8221; said Ashim Gupta, COO and CFO of UiPath.
UiPath&#8217;s management team will further discuss the company&#8217;s quarterly results on a conference call set for 5 p.m. ET.
PATH Price Action: <a href="http://benzinga.com/quote/PATH">UiPath shares</a> were up 5.95% in after-hours Thursday, trading at $13.71 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45681892/marvell-technology-stock-slips-after-q1-results-details">Marvell Technology Stock Slips After Q1 Results: Details</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/Ian+Dewar+Photography">Ian Dewar Photography</a>/Shutterstock.

Comments

UiPath

UiPath (PATH) Options

UiPath (NYSE:PATH) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL